Skip to main content

Outcome of patients with glioblastoma in Saudi Arabia: Single center experience

Research Abstract
Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, is associated with one of the worst 5 year survival rates among all human cancer types. To date, no published data are available for the outcome of this disease in Saudi Arabia. The present study performed a single‑center, retrospective cohort study to evaluate the outcome of patients with GBM in Saudi Arabia. The Comprehensive Cancer Center at King Fahad Medical city (Riyadh, Saudi Arabia) was used in the present study. All adult patients (≥18 years) diagnosed with histologically proven GBM between January 2008 and December 2013 were included in the present study. A total of 90 patients were treated during the specified period. Of this, 73 (81%) patients underwent resection and 17 (19%) had biopsy only. The majority of patients (n=88; 98%) received radiotherapy (XRT): 67 (76%) with standard and 21 (24%) with hypo‑fractionated dosage. Of the total patients, 65 (72%) received combined modality therapy [standard XRT concurrently with Temozolmide (TMZ)]. The 6 month progression‑free survival rate was 43% for all patients and 55% for the combined modality subgroup. The median overall survival (OS) for all patients was 13.7 months. However, the median OS for patients treated with combined modality was 19.7 months. In this single‑center retrospective study, the outcomes of patients with GBM were similar to those in previously reported studies. An improved outcome was associated with an improved performance status, absence of residual disease and use of adjuvant TMZ.
Research Authors
Abdullah k. Altwairgi, Waleed Algareeb, Gaaem Yahya, Ahmed M. Maklad, Moamen MOM Aly, Wafa Al Shakweer, Ali Balbaid, Eyad Alsaeed, Hussain Alhussain, Yassir Orz, Ahmed Lary and Ashraf Elyamany
Research Journal
Molecular and Clinical Oncology
Research Pages
756-762
Research Publisher
Molecular and Clinical Oncology
Research Rank
1
Research Vol
4(5)
Research Website
https://doi.org/10.3892/mco.2016.818
Research Year
2016

Development of the Use of Amorphous Silicon (ASi) Electronic Portal Imaging Devices as a Physics Tool for Routine Linear Accelerator QA

Research Abstract
Background: Electronic portal imaging device(EPID)has different dosimetric characteristics than the ionization chamber, which is considered as the gold standard detector in radiation dosimetry. The main purpose of this study was to develop the applications of EPID. Dosimetric properties of amorphous silicon EPID (aS500) need to be investigated. Materials and methods: To verify linear response with dose, images of a 10×10 cm² open field were acquired. The EPID was positioned at a fixed detector distance of 150 cm, and varying doses were delivered with monitor unit settings of 1MU and 12MU. Results: The flatness should be less than 3%. The maximum flatness value was 2.7% for field size 10×10 cm² and 1.8% for field size 18×8 cm², which are within tolerance. EPID response was compared with the chamber dose. It was found that by increasing field size, both the EPID response and chamber dose were increased. The study showed that the EPID aSi500 has the potential to be used as a relative dosimeter, making it a very simple and efficient tool for daily QA. Conclusion: All EPID measurements were performed using the linear accelerator Varian DMX. The physical characteristics measured in this work suggest that the SLIC-EPID can be used be as a relative dosimeter.
Research Authors
Gena M.A.H, Ahmed L.El-Attar, Elbadry M. Zahran, Hany El-Gamal, Moamen M.O.M. Aly
Research Journal
International Journal of Science and Research (IJSR)
Research Pages
703-708
Research Publisher
NULL
Research Rank
1
Research Vol
5(9)
Research Website
https://www.ijsr.net/
Research Year
2016

Development of the Use of Amorphous Silicon (ASi) Electronic Portal Imaging Devices as a Physics Tool for Routine Linear Accelerator QA

Research Abstract
Background: Electronic portal imaging device(EPID)has different dosimetric characteristics than the ionization chamber, which is considered as the gold standard detector in radiation dosimetry. The main purpose of this study was to develop the applications of EPID. Dosimetric properties of amorphous silicon EPID (aS500) need to be investigated. Materials and methods: To verify linear response with dose, images of a 10×10 cm² open field were acquired. The EPID was positioned at a fixed detector distance of 150 cm, and varying doses were delivered with monitor unit settings of 1MU and 12MU. Results: The flatness should be less than 3%. The maximum flatness value was 2.7% for field size 10×10 cm² and 1.8% for field size 18×8 cm², which are within tolerance. EPID response was compared with the chamber dose. It was found that by increasing field size, both the EPID response and chamber dose were increased. The study showed that the EPID aSi500 has the potential to be used as a relative dosimeter, making it a very simple and efficient tool for daily QA. Conclusion: All EPID measurements were performed using the linear accelerator Varian DMX. The physical characteristics measured in this work suggest that the SLIC-EPID can be used be as a relative dosimeter.
Research Authors
Gena M.A.H, Ahmed L.El-Attar, Elbadry M. Zahran, Hany El-Gamal, Moamen M.O.M. Aly
Research Journal
International Journal of Science and Research (IJSR)
Research Pages
703-708
Research Publisher
NULL
Research Rank
1
Research Vol
5(9)
Research Website
https://www.ijsr.net/
Research Year
2016

Development of the Use of Amorphous Silicon (ASi) Electronic Portal Imaging Devices as a Physics Tool for Routine Linear Accelerator QA

Research Abstract
Background: Electronic portal imaging device(EPID)has different dosimetric characteristics than the ionization chamber, which is considered as the gold standard detector in radiation dosimetry. The main purpose of this study was to develop the applications of EPID. Dosimetric properties of amorphous silicon EPID (aS500) need to be investigated. Materials and methods: To verify linear response with dose, images of a 10×10 cm² open field were acquired. The EPID was positioned at a fixed detector distance of 150 cm, and varying doses were delivered with monitor unit settings of 1MU and 12MU. Results: The flatness should be less than 3%. The maximum flatness value was 2.7% for field size 10×10 cm² and 1.8% for field size 18×8 cm², which are within tolerance. EPID response was compared with the chamber dose. It was found that by increasing field size, both the EPID response and chamber dose were increased. The study showed that the EPID aSi500 has the potential to be used as a relative dosimeter, making it a very simple and efficient tool for daily QA. Conclusion: All EPID measurements were performed using the linear accelerator Varian DMX. The physical characteristics measured in this work suggest that the SLIC-EPID can be used be as a relative dosimeter.
Research Authors
Gena M.A.H, Ahmed L.El-Attar, Elbadry M. Zahran, Hany El-Gamal, Moamen M.O.M. Aly
Research Journal
International Journal of Science and Research (IJSR)
Research Pages
703-708
Research Publisher
NULL
Research Rank
1
Research Vol
5(9)
Research Website
https://www.ijsr.net/
Research Year
2016

Development of the Use of Amorphous Silicon (ASi) Electronic Portal Imaging Devices as a Physics Tool for Routine Linear Accelerator QA

Research Abstract
Background: Electronic portal imaging device(EPID)has different dosimetric characteristics than the ionization chamber, which is considered as the gold standard detector in radiation dosimetry. The main purpose of this study was to develop the applications of EPID. Dosimetric properties of amorphous silicon EPID (aS500) need to be investigated. Materials and methods: To verify linear response with dose, images of a 10×10 cm² open field were acquired. The EPID was positioned at a fixed detector distance of 150 cm, and varying doses were delivered with monitor unit settings of 1MU and 12MU. Results: The flatness should be less than 3%. The maximum flatness value was 2.7% for field size 10×10 cm² and 1.8% for field size 18×8 cm², which are within tolerance. EPID response was compared with the chamber dose. It was found that by increasing field size, both the EPID response and chamber dose were increased. The study showed that the EPID aSi500 has the potential to be used as a relative dosimeter, making it a very simple and efficient tool for daily QA. Conclusion: All EPID measurements were performed using the linear accelerator Varian DMX. The physical characteristics measured in this work suggest that the SLIC-EPID can be used be as a relative dosimeter.
Research Authors
Gena M.A.H, Ahmed L.El-Attar, Elbadry M. Zahran, Hany El-Gamal, Moamen M.O.M. Aly
Research Journal
International Journal of Science and Research (IJSR)
Research Pages
703-708
Research Publisher
NULL
Research Rank
1
Research Vol
5(9)
Research Website
https://www.ijsr.net/
Research Year
2016

Evaluation the possibility of using of miRNA-21 as a prognostic and predictive factor in colorectal cancer (South Egypt Experience)

Research Abstract
micro ribonucleic acid-21 (miRNA 21) is overexpressed in multiple solid tumors, indicating that its biology is relevant to different type of cancers, in colorectal cancer (CRC), a lot of studies suggested its use as a diagnostic marker. Others as a predictive for 5-flurouracil (5 FU) sensitivity. This study was conducted to verified the significance of miRNA 21 as a prognostic and predictive marker in CRC. Patients and methods: It is a prospective study included 45 patients with stage I - IV CRC who attended at South Egypt Cancer Institute (SECI) from May 2017 to September 2018. miRNA 21 was measured by Quantitative real time polymerase chain reaction (q PCR) from peripheral blood sample and its levels of expression was correlated to the clinco pathological features of the studied patients, response to 5FU containing regimen which was assessed by response evaluation criteria in solid tumors (RECIST criteria) and to the survival. Results: High expression of the miRNA21 was significantly associated with advanced stage of CRC p 0.001, lymph node (LN) invasion p 0.001, distant metastasis p 0.01, lymphovascular invasion (LVI) p 0.01 and pre treatment level of carcinoembryonic antigen (CEA) p 0.031. Also we found that high expression of miRNA21was significantly had a bad effect on the response to 5FU containing regimen p 0.001, disease free survival (DFS) p 0.01 and overall survival (OS) p 0.01. Conclusion: miRNA 21 could be used as a non invasive prognostic and predictive marker in CRC.
Research Authors
Ashraf Zedan1, Hosny Badrawy2, Mayada Fawzy 1,, Dina Ismail Abd El Razik 2, Sanaa Saber1, Abeer Ibrahim1
Research Department
Research Journal
journal of cancer therapy
Research Pages
NULL
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2020

Risk-Adapted, Combined-Modality Therapy for
Unfavorable Pediatric Hodgkin Lymphom

Research Abstract
Background and Objectives: Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life, with long term follow up. We assess the impact of prognostic factors associated with local treatment failure of pediatric HL patients with unfavorable criteria treated with combined modality: Alternating ABVD (Doxorubicin, Bleomycin, Vinblastine and Decarbazine) and COEP (Cyclophosphamide, Oncovin, Etoposide and Prednisone) chemotherapy and response-based, involved- field radiation for newly diagnosed unfavorable pediatric HL patients, also will detect toxicities and long-term complications observed in the patients. Methods: This prospective study was carried out from January 2010 to January 2018, with a median follow up of 74 months (range 8 - 103 months). 54 patients were eligible for this study stratified into two groups: intermediate risk (IR) and high-risk group (HR). Patients were treated with (4 - 6 cycles) and (6 - 8 cycles) respectively of alternating ABVD/COEP chemotherapy followed by involved-field radiation therapy (IFRT): 15 Gy for patients achieved complete response, and 25.5 Gy for those achieved a partial response. Results: 27 patients were IR and 27 patients were HR. There were 16 treatment failures; 5 patients had progressive disease; and 11 patients had a relapse. 9 patients died from their disease progression. The 5-year overall survival (OS) and event-free survival (EFS) rates (±SE) were 81.8% ± 5.7% and 71.8% ± 6.2% respectively. Multivariate analysis revealed that the only independent factor for inferior OS was radiotherapy. Conclusion: Treatment results of unfavourable HL patients in our study are satisfactory for with IR group but not for HR group who needs intensification of therapy. Radiotherapy is considered as a cornerstone in the treatment of the patients with unfavourable criteria with better assessment of early responders needed by PET-CT to identify patients at risk for relapse.
Research Authors
Amany M. Ali1, Amira M. Mohamed1, Shimaa Ahmed2*, Mohamed Abdallah3, Tarek M. Alsaba4,
Samer Mansour5
Research Department
Research Journal
Journal of Cancer Therapy
Research Pages
545-558
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
http://www.scirp.org/journal/jct
Research Year
2018

Risk-Adapted, Combined-Modality Therapy for
Unfavorable Pediatric Hodgkin Lymphom

Research Abstract
Background and Objectives: Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life, with long term follow up. We assess the impact of prognostic factors associated with local treatment failure of pediatric HL patients with unfavorable criteria treated with combined modality: Alternating ABVD (Doxorubicin, Bleomycin, Vinblastine and Decarbazine) and COEP (Cyclophosphamide, Oncovin, Etoposide and Prednisone) chemotherapy and response-based, involved- field radiation for newly diagnosed unfavorable pediatric HL patients, also will detect toxicities and long-term complications observed in the patients. Methods: This prospective study was carried out from January 2010 to January 2018, with a median follow up of 74 months (range 8 - 103 months). 54 patients were eligible for this study stratified into two groups: intermediate risk (IR) and high-risk group (HR). Patients were treated with (4 - 6 cycles) and (6 - 8 cycles) respectively of alternating ABVD/COEP chemotherapy followed by involved-field radiation therapy (IFRT): 15 Gy for patients achieved complete response, and 25.5 Gy for those achieved a partial response. Results: 27 patients were IR and 27 patients were HR. There were 16 treatment failures; 5 patients had progressive disease; and 11 patients had a relapse. 9 patients died from their disease progression. The 5-year overall survival (OS) and event-free survival (EFS) rates (±SE) were 81.8% ± 5.7% and 71.8% ± 6.2% respectively. Multivariate analysis revealed that the only independent factor for inferior OS was radiotherapy. Conclusion: Treatment results of unfavourable HL patients in our study are satisfactory for with IR group but not for HR group who needs intensification of therapy. Radiotherapy is considered as a cornerstone in the treatment of the patients with unfavourable criteria with better assessment of early responders needed by PET-CT to identify patients at risk for relapse.
Research Authors
Amany M. Ali1, Amira M. Mohamed1, Shimaa Ahmed2*, Mohamed Abdallah3, Tarek M. Alsaba4,
Samer Mansour5
Research Department
Research Journal
Journal of Cancer Therapy
Research Pages
545-558
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
http://www.scirp.org/journal/jct
Research Year
2018

Risk-Adapted, Combined-Modality Therapy for
Unfavorable Pediatric Hodgkin Lymphom

Research Abstract
Background and Objectives: Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life, with long term follow up. We assess the impact of prognostic factors associated with local treatment failure of pediatric HL patients with unfavorable criteria treated with combined modality: Alternating ABVD (Doxorubicin, Bleomycin, Vinblastine and Decarbazine) and COEP (Cyclophosphamide, Oncovin, Etoposide and Prednisone) chemotherapy and response-based, involved- field radiation for newly diagnosed unfavorable pediatric HL patients, also will detect toxicities and long-term complications observed in the patients. Methods: This prospective study was carried out from January 2010 to January 2018, with a median follow up of 74 months (range 8 - 103 months). 54 patients were eligible for this study stratified into two groups: intermediate risk (IR) and high-risk group (HR). Patients were treated with (4 - 6 cycles) and (6 - 8 cycles) respectively of alternating ABVD/COEP chemotherapy followed by involved-field radiation therapy (IFRT): 15 Gy for patients achieved complete response, and 25.5 Gy for those achieved a partial response. Results: 27 patients were IR and 27 patients were HR. There were 16 treatment failures; 5 patients had progressive disease; and 11 patients had a relapse. 9 patients died from their disease progression. The 5-year overall survival (OS) and event-free survival (EFS) rates (±SE) were 81.8% ± 5.7% and 71.8% ± 6.2% respectively. Multivariate analysis revealed that the only independent factor for inferior OS was radiotherapy. Conclusion: Treatment results of unfavourable HL patients in our study are satisfactory for with IR group but not for HR group who needs intensification of therapy. Radiotherapy is considered as a cornerstone in the treatment of the patients with unfavourable criteria with better assessment of early responders needed by PET-CT to identify patients at risk for relapse.
Research Authors
Amany M. Ali1, Amira M. Mohamed1, Shimaa Ahmed2*, Mohamed Abdallah3, Tarek M. Alsaba4,
Samer Mansour5
Research Department
Research Journal
Journal of Cancer Therapy
Research Member
Research Pages
545-558
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
http://www.scirp.org/journal/jct
Research Year
2018

Risk-Adapted, Combined-Modality Therapy for
Unfavorable Pediatric Hodgkin Lymphom

Research Abstract
Background and Objectives: Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life, with long term follow up. We assess the impact of prognostic factors associated with local treatment failure of pediatric HL patients with unfavorable criteria treated with combined modality: Alternating ABVD (Doxorubicin, Bleomycin, Vinblastine and Decarbazine) and COEP (Cyclophosphamide, Oncovin, Etoposide and Prednisone) chemotherapy and response-based, involved- field radiation for newly diagnosed unfavorable pediatric HL patients, also will detect toxicities and long-term complications observed in the patients. Methods: This prospective study was carried out from January 2010 to January 2018, with a median follow up of 74 months (range 8 - 103 months). 54 patients were eligible for this study stratified into two groups: intermediate risk (IR) and high-risk group (HR). Patients were treated with (4 - 6 cycles) and (6 - 8 cycles) respectively of alternating ABVD/COEP chemotherapy followed by involved-field radiation therapy (IFRT): 15 Gy for patients achieved complete response, and 25.5 Gy for those achieved a partial response. Results: 27 patients were IR and 27 patients were HR. There were 16 treatment failures; 5 patients had progressive disease; and 11 patients had a relapse. 9 patients died from their disease progression. The 5-year overall survival (OS) and event-free survival (EFS) rates (±SE) were 81.8% ± 5.7% and 71.8% ± 6.2% respectively. Multivariate analysis revealed that the only independent factor for inferior OS was radiotherapy. Conclusion: Treatment results of unfavourable HL patients in our study are satisfactory for with IR group but not for HR group who needs intensification of therapy. Radiotherapy is considered as a cornerstone in the treatment of the patients with unfavourable criteria with better assessment of early responders needed by PET-CT to identify patients at risk for relapse.
Research Authors
Amany M. Ali1, Amira M. Mohamed1, Shimaa Ahmed2*, Mohamed Abdallah3, Tarek M. Alsaba4,
Samer Mansour5
Research Department
Research Journal
Journal of Cancer Therapy
Research Member
Research Pages
545-558
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
http://www.scirp.org/journal/jct
Research Year
2018
Subscribe to